Role of dopaminergic agonists;La place des agonistes dopaminergiques

Revue Neurologique

Volumn 156, Issue SUPPL. 2 BIS, 2000, Pages 98-104

  Rascol, O ^a,b   Montastruc, J L ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 0033913414     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. ADLER CH, SETHI KD, HAUSER RA, DAVIS TL, HAMMERSTAD JP, BERTONI J, TAYLOR RL, SANCHEZ-RAMOS J, O'BRIEN CF, for the Ropinirole Study Group. (1997). Ropinirole for the treatment of early Parkinson's disease. Neurology, 49: 393-399.
2. BARONE P, BRAVI D, BERMEJO-PAREJA F, MARCONI R, KULISEVSKY J, MALAGU S, WEISER R, ROST N, the Pergolide Monotherapy Study Group. (1999). Pergolide monotherapy in the treatment of early PD. A randomized, controlled study. Neurology, 53: 573-579.
3. BEDARD PJ, DI PAOLO T, FALARDEAU P, BOUCHER R. (1986). Chronic treatment with levodopa, but not brornocriptine, induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with 3H-spiperone binding. Brain Res, 379: 294-299.
4. BROOKS DJ, ABBOTT RJ, LEES AJ, MARTIGNONI E, PHILCOX DV, RASCOL O, ROOS RAC, SAGER HJ. (1998). A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol, 21: 101-107.
5. COOPER JA, SAGAR HJ, DOHERTY M, JORDAN N, TIDSWELL P, SULLIVAN EV. (1992). Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A Follow-up study of untreated patients. Brain, 115: 1701-1725.
6. FERREIRA J, GALITZKY M, MONTASTRUC JL, RASCOL O. (2000). Sleep attacks and Parkinson's disease treatment. Lancet, 355: 1333-1334.
7. FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S. (1999). Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology, 52: 1908-1910.
8. GIMÉNEZ-ROLDAN S, TOLOSA E, BURGUERA JA, CHACON J, LIANO H, FORCADEL F. (1997). Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol, 20: 67-76.
9. HELY MA, MORRIS JGL, REID WGJ, O'SULLIVAN DJ, WILLIAMSON PM, RAIL D, BROE GA, MARGRIE S. (1994). The Sydney multicentre study of Parkinson's disease: a randomised,prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry, 57: 903-910.
10. HELY MA, MORRIS JGL, TRAFICANTE R, REID WGJ, O'SULLIVAN DJ, WILLIAMSON PM. (1999). The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry, 67: 300-307.
11. HERSKOVITS E, YORIO A, LESTON J. (1988). Long-term bromocriptine treatment in de novo parkinsonian patients. Medicina, 48: 345-350.
12. HUBBLE JP, KOLLER WC, CUTTLER NR, SRAMEK JJ, FRIEDMAN J, GOETZ C, RANHOSKY A, KORTS D, ELVIN A. (1995). Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol, 18: 338-347.
13. JUNCOS JL, ENGBER TM, RAISMAN R, CHASE TN. (1989). Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol, 25: 473-478.
14. KORCZYN AD, BROOKS DJ, BRUNT ER, POEWE WH, RASCOL O, STOCCHI F, on behalf of the 053 Study Group. (1998). Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord, 13: 46-51.
15. KORCZYN AD, BRUNT ER, LARSEN JP, NAGY Z, POEWE WH, RUGGIERI S, for the 053 Study Group. (1999). A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology, 53: 364-370.
16. LEES AJ, STERN GM. (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 44: 1020-1023.
17. LIBMAN I, GAWEL MJ, RIOPELLE RJ, BOUCHARD S. (1987). A comparison of bromocriptine (Parlodel○) and levodopa-carbidopa (Sinemet○) for treatment of "de novo" Parkinson's disease patients. Can J Neurol Sci, 14: 576-580.
18. LUQUIN MR, LAGUNA J, OBESO JA. (1992). Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol, 31: 551-554.
19. MONTASTRUC JL, RASCOL O, RASCOL A. (1989). A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry, 52: 773-775.
20. MONTASTRUC JL, RASCOL O, SENARD JM, RASCOL A. (1994). A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry, 57: 1034-1038.
21. NAKANISHI T, IWATA M, GOTO I, KANAZAWA I, KOWA H, MANNEN T, MIZUNO Y, NISHITANI H, OGAWA N, TAKAHASHI A, TASHIRO K, TOHGI H, YANAGISAWA N. (1992). Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final Report. Eur Neurol, 32 (suppl): 9-22.
22. OLANOW CW, HAUSER RA, GAUGER L, MALAPIRA T, KOLLER W, HUBBLE J, BUSHENBARK K, LILIENFELD D, ESTERLITZ J. (1995). The effect of deprenyl and levodopa on the progressoin of Parkinson's disease. Ann Neurol, 38: 771-777.
23. PARKINSON STUDY GROUP. (1997). Safety and efficacy of pramipexole in early Parkinson Disease. A randomized dose-ranging study. JAMA, 270: 125-130.
24. PARKINSON'S DISEASE RESEARCH GROUP IN THE UNITED KINGDOM. (1993). Comparisons of therapeutics effects of levodopa, levodopa and selegiline, and bromocriptine in patients wiht early, mild Parkinson's disease: three year interim report. Br Med J, 307: 469-472.
25. PEARCE RK, BANERJI T, JENNER P, MARSDEN CD. (1998). De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord, 13: 234-241.
26. PRZUNTEK H, WELZEL D, BLÜMNER E, DANIELCZYK W, LETZEL H, KAISER HJ, KRAUS PH, RIEDERER P, SCHWARZMANN D, WOLF H, UBERLA K. (1992). Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eu J Clin Pharmacol, 43: 357-363.
27. PRZUNTEK H, WELZEL D, GERLACH M, BLÜMNER E, DANIELCZYK W, KAISER HJ, KRAUS PH, LETZEL H, RIEDERER P, UBERLA K. (1996). Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associted motor side effects. Long-term results of the PRADO study. J Neurol Transm, 103: 699-715.
28. RASCOL A, GUIRAUD B, MONTASTRUC JL. DAVID J, CLANET M. (1979). Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry, 42: 143-150.
29. RASCOL O, BROOKS DJ, BRUNT ER, KORCZYN AD, POEWE WH, STOCCHI F, on behalf of the 056 Study Group. (1998). Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord, 13: 39-45.
30. RASCOL O. (1999). Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques. Rev Neurol, 155: 35-42.
31. RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE, for the 056 Study Group. (2000). A Five-year study of the incidence of dysknesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med, 342: 1484-1491.
32. RINNE UK. (1989). Lisurice, a dopamine agonist in the treatment of early Parkinson's disease. Neurology, 39: 336-339.
33. RINNE UK, BRACCO F, CHOUZA C, DUPONT E, GERSHANIK O, MARTI MASSO JF, MONTASTRUC JL, MARSDEN CD, DUBINI A, GRIMALDI NOR, and the PKDS009 Collaborative Study Group. (1997). Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology, 48: 363-368.
34. RINNE UK, BRACCO F, CHOUZA C, DUPONT E, GERSHANIK O, MARTI MASSO JF, MONTASTRUC JL, MARSDEN CD, and the PKDS009 Study Group. (1998). Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs, 55 suppl: 23-30.
35. RIOPELLE RJ. (1987). Bromocriptine and the clinical spectrum of Parkinson's disease. Can J Neurol Sci, 14 (suppl): 455-459.
36. SETHI KD, O'BRIEN CF, HAMMERSTAD JP, ADLER CH, DAVIS TL, TAYLOR RL, SANCHEZ-RAMOS J, BERTONI JM, HAUSER RA. (1998). Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol, 55: 1211-1216.
37. SHANNON KM, BENNETT JP, FRIEDMAN JH, for the Pramipexole Study Group. (1997). Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology, 49: 724-728.
38. STAAL-SCHREINEMACHERS AL, WESSELING H, KAMPHUIS DJ, BURG WVD, LAKKE JPWF. (1986). Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology, 36: 291-293.
39. UK Bromocriptine Research Group. (1989). Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry, 52: 77-82.
40. VERMERSCH P, FONDARAI J, PETIT H. (1991). Étude randomisée sur une année de l'asscciation précoce L-dopa/lisuride dans la maladie de Parkinson. Therapie, 46: 481-486.
41. WEINER WJ, FACTOR SA SANCHEZ-RAMOS JR, SINGER C, SHELDON C, CORNELIUS L, INGENITO A. (1993). Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology, 43: 21-27.